Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
ASKA, Renascience Wind Up PMS Drug Collab after PII Miss
ASKA Pharmaceutical said on November 25 that it has called off its option agreement for pyridoxamine (RS8001), a vitamin B6 agent being developed by Renascience for premenstrual syndrome (PMS), after a PII failure. Renascience, a Tohoku University offshoot, has been…
To read the full story
Related Article
- Renascience, ASKA Pair Up to Develop Pyridoxamine
December 25, 2019
BUSINESS
- Takeda Swings to Loss after Booking Amitiza Litigation Charge
June 8, 2026
- Kaken Files Head Lice Treatment in Japan
June 8, 2026
- UCB Japan Seeks Pediatric Use, Dry Syrup Approval for Briviact
June 8, 2026
- Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
June 8, 2026
- Nobelpharma’s Nobelzin Makes China Debut for Wilson Disease
June 8, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…